Disrupting Biotech Stocks Look Now! INBS, RMED, IPA, ENZC

Getting your Trinity Audio player ready...

Investors are almost always on the lookout for disruptive companies which can shake up their sectors and that is especially true for innovation focussed sectors like biotech. Every once in a while a number of companies come up in the biotech sector which fit the bill. This article is going to provide you with a look into four biotech companies that are disrupting the sector at this point.

Intelligent Bio Solutions Inc (NASDAQ:INBS) – Throughout the year so far the rapid diagnostics solutions provider Intelligent Bio Solutions has managed to hit a number of key milestones. In January the company had managed to make a path-breaking improvement in thin biosensors. It also added five new clients to its Intelligent Fingerprint solution.

In March 2023 the company also regained compliance with NASDAQ and the following month Intelligent Bio Solutions had been granted the United Kingdom patent for a Fingerprint Drug Screening System cartridge reader. The company is also working on a range of upcoming products which could further disrupt the biotech industry.

Ra Medical Systems Inc (NYSEAMERICAN:RMED) – On June 12 the company announced that its fully owned subsidiary Catheter Precision Inc had hit a major milestone. It was announced that its first customer Heart Hospital of New Mexico at Lovelace Medical Center had deployed its solution VIVO to complete 100 ventricular ablation procedures.

VIVO is a 3D imaging system of a non-invasive nature that helps in identifying the earliest possible activation of a ventricular arrhythmia. It was a significant new development since it demonstrated that the benefits provided by VIVO were being recognized.

ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) – The company is a major player in the artificial intelligence powered Biotherapeutic research and technology space. On June 13 the company announced that its subsidiary unit BioStrand had been successful in discovering a new use case for the Information Integration Dilemma (IID) solution.

The IID had been a confounding thing for investors and researchers for a long time and hence the latest development was a significant one for ImmunoPrecise Antibodies.

Enzolytics Inc (OTCMKTS:ENZC) – Drug development biotech firm Enzolytics Inc provided an update about the sale of its business units Virogenetics Inc and Biogenysis Inc to Sagaliam Acquisition Corp, a special purpose acquisition company. The company announced that in order to facilitate the sales of the two fully owned subsidiaries negotiations had started between the existing sponsor of Sagaliam and BN Holdings Trust.